FDA Approves Ramucirumab Injection in Combination with Erlotinib for NSCLC
The FDA approved ramucirumab injection in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 mutations. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Lilly's Cyramza (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
INDIANAPOLIS, May 29, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cyramza® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 29, 2020 Category: Drugs & Pharmacology Source Type: news
Low-Dose Erlotinib Shows Promise in Elderly, Frail Patients with EGFR+ NSCLC
A phase II study indicated that low-dose erlotinib (Tarceva) appears to be safe and effective in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 22, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA grants Breakthrough Therapy Designation for Roche ’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease
Basel, 3 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet ® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD[1]. The study represented the first randomised controlled trial to exclusively enroll patients with progressive fibrosing uILD.“Today’s milestone for Esbriet builds on our continued commitment to improving the standard of care for people ...
Source: Roche Investor Update - March 3, 2020 Category: Pharmaceuticals Source Type: news
FDA ODAC Votes on Safety and Efficacy of Ramucirumab Plus Erlotinib for EGFR+ NSCLC
The FDA Oncologic Drugs Advisory Committee voted 6 to 5 that ramucirumab plus erlotinib demonstrated a favorable benefit and risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Drug Extends Overall Survival in Some Lung Cancer Patients by 20% Drug Extends Overall Survival in Some Lung Cancer Patients by 20%
Final results of AstraZeneca ' s FLAURA trial show a 20% increase in median overall survival among patients given osimertinib for untreated, advanced non-small-cell lung cancer with an epidermal growth factor receptor mutation, compared to patients who receive gefitinib or erlotinib.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib
MANALAPAN, N.J., Nov. 13, 2019 -- (Healthcare Sales & Marketing Network) -- Armas Pharmaceuticals Inc. (Armas) is announcing the launch of generic Tarceva® (a trademark of Genentech USA, Inc) Tablets. Erlotinib is now available in 25mg, 100mg and 150m... Biopharmaceuticals, Generics, Oncology, Product Launch Armas Pharmaceuticals, Erlotinib, Tarceva, Genentech, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2019 Category: Pharmaceuticals Source Type: news
erlotinib (Tarceva)
Title: erlotinib (Tarceva)Category: MedicationsCreated: 11/28/2004 12:00:00 AMLast Editorial Review: 8/27/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 27, 2019 Category: Cancer & Oncology Source Type: news
RELAY: Ramucirumab Shows Benefit in Metastatic Lung Cancer
The RELAY trial compared the combination of ramucirumab plus erlotinib vs erlotinib alone in patients with metastatic non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
Gefitinib, erlotinib preferred in EGFR-mutation+ NSCLC in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news
Veracyte Finds Ally in J & amp;J for Early Lung Cancer Detection
A new collaboration between Johnson & Johnson Innovation and Veracyte, a genomic diagnostics company, will focus on the detection of lung cancer. The long-term agreement will be used to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable.
Under terms of the agreement, South San Francisco, CA - based Veracyte and the Lung Cancer Initiative at Johnson & Johnson, whose mission is to prevent, intercept, and cure lung cancer, will combine clinical study cohorts involving more than 5,000 patients with multiple years of cl...
Source: MDDI - January 4, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Testing Source Type: news
Adjuvant Erlotinib in Lung Cancer Prolongs Disease-Free Survival
(MedPage Today) -- No recurrence 2 years after surgery in almost 90% of EGFR+ NSCLC patients (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 21, 2018 Category: Primary Care Source Type: news
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue
Due to the high rate ofEGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease. (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2018 Category: Cancer & Oncology Authors: Emily Wynja, MSIV, Jenna Hove, BSN, Steven F. Powell, MD Source Type: news
Biodesix Makes the Case for VeriStrat Through New Study
The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncologist. The study demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer (NSCLC).
VeriStrat is a multivariate, mass-spectrometry based test that measures circulating proteins in the blood serum or plasma of patients with NSCLC.
Test results assign a good (VS Good) or poor (VS Poor) classification to patient samples. Multiple studies support that patients with a VS Good result have a better prognosis than patients with a VS Poor result, independent of curr...
Source: MDDI - August 31, 2018 Category: Medical Devices Tags: IVD Business Source Type: news
Lung cancer drug likely to be approved for wider NHS use
NICE set to approve greater use of pembrolizumab Related items fromOnMedica First new cancer drug introduced under Cancer Drugs Fund Cigars and pipes raise mortality risk independent of cigarettes Public drastically underestimates cannabis risks Erlotinib prolongs survival in lung cancer New targeted drug could help treat advanced cancers (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 7, 2018 Category: UK Health Source Type: news
